Added Consent Demands Will Discourage Device Improvements - AdvaMed
This article was originally published in The Gray Sheet
Executive Summary
Patient authorization requirements included in the final medical privacy rule will render informed consent superfluous and create obstacles to incremental medical device improvements, according to AdvaMed.
You may also be interested in...
Business Associate Provision Should Be Dropped From Privacy Rule - BCBSA
Provisions requiring covered entities to establish contracts with business associates that receive identifiable information should be eliminated from HHS' medical privacy regulations, the Blue Cross/Blue Shield Association is recommending.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.